The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | H | Systemic hormonal preparations, excl. Sex hormones and insulins | |
| 2 | H03 | Thyroid therapy | |
| 3 | H03B | Antithyroid preparations | |
| 4 | H03BB | Sulfur-containing imidazole derivatives | |
| 5 | H03BB01 | Carbimazole |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 15 mg |
| Active Ingredient | Description | |
|---|---|---|
| Carbimazole |
Carbimazole, a thionamide, is a pro-drug which undergoes rapid and virtually complete metabolism to the active metabolite, thiamazole, also known as methimazole. The method of action is believed to be inhibition of the organification of iodide and the coupling of iodothyronine residues which in turn suppress the synthesis of thyroid hormones. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| NEOMERCAZOLE Tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
